ZA200203704B - Pharmaceutical formulations containing zolmitriptan. - Google Patents

Pharmaceutical formulations containing zolmitriptan.

Info

Publication number
ZA200203704B
ZA200203704B ZA200203704A ZA200203704A ZA200203704B ZA 200203704 B ZA200203704 B ZA 200203704B ZA 200203704 A ZA200203704 A ZA 200203704A ZA 200203704 A ZA200203704 A ZA 200203704A ZA 200203704 B ZA200203704 B ZA 200203704B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
ZA200203704A
Other languages
English (en)
Inventor
Alan Roy Dearn
Simon John Summers
Sarah Louise Williamson
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200203704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200203704B publication Critical patent/ZA200203704B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA200203704A 1999-12-03 2002-05-09 Pharmaceutical formulations containing zolmitriptan. ZA200203704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ZA200203704B true ZA200203704B (en) 2003-10-29

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203704A ZA200203704B (en) 1999-12-03 2002-05-09 Pharmaceutical formulations containing zolmitriptan.

Country Status (28)

Country Link
US (2) US6750237B1 (de)
EP (1) EP1237551B1 (de)
JP (1) JP2003515559A (de)
KR (1) KR100670092B1 (de)
CN (1) CN1222287C (de)
AT (1) ATE291914T1 (de)
AU (1) AU778092B2 (de)
BR (1) BRPI0016138B8 (de)
CA (1) CA2392050C (de)
CZ (1) CZ301528B6 (de)
DE (1) DE60019162T2 (de)
EE (1) EE05305B1 (de)
ES (1) ES2236001T3 (de)
GB (2) GB9928578D0 (de)
HK (3) HK1048442B (de)
HU (1) HU229458B1 (de)
IL (2) IL149578A0 (de)
IS (1) IS2135B (de)
MX (1) MXPA02005319A (de)
NO (1) NO322119B1 (de)
NZ (1) NZ518862A (de)
PL (1) PL200679B1 (de)
PT (1) PT1237551E (de)
RU (1) RU2255736C2 (de)
SK (1) SK287228B6 (de)
UA (1) UA75059C2 (de)
WO (1) WO2001039772A1 (de)
ZA (1) ZA200203704B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
WO2006055964A2 (en) * 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
ATE502921T1 (de) * 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2012048710A1 (en) 2010-10-15 2012-04-19 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
RU2670272C2 (ru) 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (de) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chirale spezifische borhaltige verbindungen und deren verwendung in der behandlung von krebs oder amyloidose
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
AU1715701A (en) 2001-06-12
CZ301528B6 (cs) 2010-04-07
BR0016138A (pt) 2002-08-06
NZ518862A (en) 2004-02-27
HK1048445A1 (en) 2003-04-04
GB0214845D0 (en) 2002-08-07
EP1237551B1 (de) 2005-03-30
IL149578A (en) 2008-04-13
ES2236001T3 (es) 2005-07-16
WO2001039772A1 (en) 2001-06-07
EE200200283A (et) 2003-06-16
JP2003515559A (ja) 2003-05-07
BRPI0016138B8 (pt) 2021-05-25
IS6394A (is) 2002-05-24
GB2373726A (en) 2002-10-02
HUP0203597A3 (en) 2005-07-28
DE60019162D1 (de) 2005-05-04
US20040214899A1 (en) 2004-10-28
SK7532002A3 (en) 2002-12-03
KR100670092B1 (ko) 2007-01-17
DE60019162T2 (de) 2006-02-02
GB2373726B (en) 2004-10-20
PL200679B1 (pl) 2009-01-30
NO20022525D0 (no) 2002-05-28
UA75059C2 (uk) 2006-03-15
HK1048442A1 (en) 2003-04-04
HU229458B1 (en) 2013-12-30
HUP0203597A2 (hu) 2003-02-28
RU2255736C2 (ru) 2005-07-10
RU2002117649A (ru) 2004-01-27
CN1222287C (zh) 2005-10-12
NO20022525L (no) 2002-05-28
PT1237551E (pt) 2005-07-29
GB9928578D0 (en) 2000-02-02
HK1048442B (zh) 2005-05-13
IS2135B (is) 2006-08-15
EP1237551A1 (de) 2002-09-11
IL149578A0 (en) 2002-11-10
KR20020058051A (ko) 2002-07-12
CA2392050C (en) 2009-11-24
AU778092B2 (en) 2004-11-18
CN1402636A (zh) 2003-03-12
HK1048445B (zh) 2005-08-26
BR0016138B1 (pt) 2013-09-10
US6750237B1 (en) 2004-06-15
HK1053430A1 (en) 2003-10-24
US7220767B2 (en) 2007-05-22
PL357597A1 (en) 2004-07-26
MXPA02005319A (es) 2002-12-06
CZ20021901A3 (cs) 2002-11-13
EE05305B1 (et) 2010-06-15
ATE291914T1 (de) 2005-04-15
SK287228B6 (sk) 2010-03-08
CA2392050A1 (en) 2001-06-07
NO322119B1 (no) 2006-08-14

Similar Documents

Publication Publication Date Title
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
GB0005251D0 (en) Therapeutic compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MY119403A (en) Novel compounds with analgesic effect.
MY129356A (en) Electrospun pharmaceutical compositions
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HK1030885A1 (en) The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease
SE9802208D0 (sv) Novel compounds
IL141914A0 (en) Dosage form comprising liquid formulation
AU2001289606A1 (en) Dry powder formulation comprising racecadotril
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
PL348202A1 (en) Pharmaceutically active composition and dispensing device
AP2000001950A0 (en) Paroxetine maleate.
ES2131482A1 (es) Formulacion acuosa de bambuterol.
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
ATE247976T1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel